Laidlaw Group’s Anika Therapeutics ANIK Stock Holding History

Laidlaw Group’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-5,040	Closed	-$207K	–	76
2015 Q1	$207K	Hold	5,040	–	–	0.1%	76
2014 Q4	$205K	Buy	+5,040	New	+$197K	0.1%	80
2014 Q3	–	Sell	-5,040	Closed	-$234K	–	82
2014 Q2	$234K	Buy	+5,040	New	+$224K	0.12%	77

Other funds holding ANIK

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

LCP

Lombardia Capital Partners Pasadena, California $110M AUM 13.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Laidlaw Group's ANIK Position: Q2 2015 in Review

Laidlaw Group sold out of Anika Therapeutics (ANIK) in Q2 2015, closing a stake of 5,040 shares — an estimated $207K sold.

Laidlaw Group first reported a position in ANIK in Q2 2014 and held it in 3 quarters. The position peaked at $234K in Q2 2014. 136 funds tracked by Wall St. Rank hold ANIK as of Q2 2015.

Laidlaw Group reported no remaining Anika Therapeutics position as of Q2 2015 after selling out during the quarter.
Laidlaw Group sold 5,040 Anika Therapeutics shares in Q2 2015, an estimated $207K.
Laidlaw Group first reported a position in Anika Therapeutics in Q2 2014 and held it in 3 quarters.
Laidlaw Group's Anika Therapeutics position peaked at $234K in Q2 2014.
136 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2015.

Based on Laidlaw Group's 13F filing for Q2 2015, filed 31 Jul 2015.